Patents by Inventor Kai Rosport

Kai Rosport has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20210130451
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: MORPHOSYS AG
    Inventors: Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
  • Treatment for rheumatoid arthritis
    Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • Use of EDG2 receptor in an animal model of heart failure
    Patent number: 7169612
    Abstract: Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: January 30, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Evi Kostenis, Paulus Wohlfart, Jochen Huber, Kai Rosport, Andreas Bueltmann, Christine Baumgartner, Götz Muench, Martin Ungerer
  • Use of EDG2 receptor in an animal model of heart failure
    Publication number: 20040132182
    Abstract: Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.
    Type: Application
    Filed: November 12, 2003
    Publication date: July 8, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Evi Kostenis, Paulus Wohlfart, Jochen Huber, Kai Rosport, Andreas Bueltmann, Christine Baumgartner, Gotz Muench, Martin Ungerer
  • Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
    Publication number: 20030049258
    Abstract: A method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle i by administering an agent capable of binding to a phosducin binding site of G&bgr;&ggr; is provided. Said phosducin binding site is preferably a binding site of N-terminal truncated phosducin. Further, methods of identifying compounds capable of increasing the contractility of a heart muscle and methods of identifying compounds capable of inhibiting G&bgr;&ggr;-mediated processes are provided.
    Type: Application
    Filed: September 11, 2001
    Publication date: March 13, 2003
    Inventors: Martin Ungerer, Gotz Munch, Christine Baumgartner, Kai Rosport, Karl-Ludwig Laugwitz, Martin Lohse